09:01pm Monday 18 December 2017

For most children with HIV and low immune cell count, cells rebound after treatment

Most children with HIV who have low levels of a key immune cell eventually recover levels of this cell after beginning treatment, according to a study by researchers funded by the National Institutes of Health.

“The comparatively few children whose CD4+ cells failed to rebound did not appear to be at any greater risk for serious infection than children with higher CD4+ counts.”

Rohan Hazra
Chief, Maternal and Pediatric Infectious Disease Branch, NICHD

Failure of CD4+ T cells External Web Site Policy, a major target of HIV, to rebound after the virus has been suppressed with medication occurs in about 15 percent of adult patients and is associated with serious, life-threatening illnesses. The researchers conducted the current study to find out to what extent children who were infected with HIV around the time of birth might be at risk for this condition and whether this failure carried with it a major risk for serious infection.

“The good news is that this condition occurs only infrequently in young children with HIV,” said study author Rohan Hazra, chief of the Maternal and Pediatric Infectious Disease Branch at NIH’s Eunice Kennedy ShriverNational Institute of Child Health and Human Development, which provided much of the funding for the study. “The comparatively few children whose CD4+ cells failed to rebound did not appear to be at any greater risk for serious infection than children with higher CD4+ counts.”

He added that the findings do not appear to change treatment recommendations for children with HIV, which include antiretroviral drugs to suppress the virus and periodic follow-up examinations to detect the first signs of any serious infections.

The findings were published online in AIDS, and the study was conducted by a team of researchers at several institutions in the United States and Brazil. The study’s first author was Paul Krogstad of the David Geffen School of Medicine at the University of California, Los Angeles.

To conduct their analysis, the researchers reviewed data from three research networks caring for more than 3,700 children in the U.S., Central and South America, and the Caribbean who were infected with HIV before or during birth. The researchers followed the CD4+ cell counts of 933 children who were at least 5 years old when they started anti-HIV treatment. Healthy CD4+ cell counts range from 500-1,200 cells per blood sample. Fewer than 500 cells per sample is considered low, and 200 or fewer per sample is considered very low. After one year of anti-HIV treatment, 86 percent of children in the study achieved CD4+ counts of 500 or more. After two years of anti-HIV treatment, 92 percent surpassed this threshold.

The researchers also reviewed the children’s records for signs of serious illness during the course of their treatment. Known as CDC Category C events, these illnesses are a sign of the seriously weakened immune system seen in people with AIDS. A total of nine children experienced such events. The occurrence of these events did not differ statistically between those having CD4+ cell counts below 500 at the time of the event (four children) and those with counts above 500 (five children).

The study authors noted that compared to adults with low CD4+ counts at the beginning of treatment, CD4+ counts in children increase to 500 or more with time after treatment has begun. Yet, despite such increases, some children had Category C conditions or other significant illnesses during the first three years of HIV treatment. The researchers called for additional studies to understand this higher risk of illness.

Additional funding was provided by the following NIH institutes: The National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases, the Office of AIDS Research, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Deafness and Other Communication Disorders, the National Heart Lung and Blood Institute, the National Institute of Dental and Craniofacial Research, and the National Institute on Alcohol Abuse and Alcoholism.

About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit the Institute’s website at http://www.nichd.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###


Share on:
or:

Health news